In contrast to systemic inhibition of this vital transcription factor that would have a negative impact on neuronal survival, as shown in recent studies utilizing sulfasalazine inhibitor [95] or a knockout mouse model [96], our experimental data strongly endorse astroglial NF-κB as a potential target for a cell-level inhibition in glaucoma therapy. The gene discussed is NFKB1; the disease is glaucoma.